Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
2
Transplant cases since reimbursement listing (cumulative, cases)Wording
Definitive
How definitive the wording is.Announced details
Regenerative medicine product “ReHeartⓇ”
Applicable field (uses covered by this announcement)
Transplant procedures involving regenerative medicine products; use under national health insurance coverage
Launch date27 October 2026 (second transplant procedure completed)
What the company reported numerically
Usage history
Second transplant procedure since reimbursement listing (as of 27 October 2026)
Relationship between the counterparty and the company
Cuorips Inc.4894
Relationship with the Company
Medical institution where transplantation of ReHeart, developed by Cuorips Inc., was performed
CounterpartyKyushu University Hospital
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine product “ReHeartⓇ” |
| Counterparty | Kyushu University Hospital |
| Relationship with the Company | Medical institution where transplantation of ReHeart, developed by Cuorips Inc., was performed |
| Launch date | 27 October 2026 (second transplant procedure completed) |
| Applicable area | Transplant procedures involving regenerative medicine products; use under national health insurance coverage |
| Usage history | Second transplant procedure since reimbursement listing (as of 27 October 2026) |
Items this document does not state (12)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company says it will work to ensure safety and promote adoption so that ReHeart can reach patients who need it.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.